Cited by 150Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchMitochondrial Function and Pathology

Reduced Posterior Cingulate Mitochondrial Activity in Expired Young Adult Carriers of the APOE ε4 Allele, the Major Late-Onset Alzheimer's Susceptibility Gene

Open access
Valla, Jon, Yaari, Roy, Wolf, Andrew B., Kusne, Yael, Beach, Thomas G., Roher, Alex E., Corneveaux, Jason J., Huentelman, Matthew J. +2 more·2010·Journal of Alzheimer s Disease

Abstract

In vivo PET imaging studies of young-adult carriers of the apolipoprotein E ε4 allele (APOEε4), the major Alzheimer's disease (AD) susceptibility gene, have demonstrated declines in glucose metabolism in brain areas later vulnerable to AD, such as posterior cingulate cortex, decades before the possible onset of symptoms. We have previously shown in postmortem studies that such metabolic declines in AD are associated with brain regional mitochondrial dysfunction. To determine whether young adult at-risk individuals demonstrate similar mitochondrial functional decline, we histochemically assessed postmortem tissues from the posterior cingulate cortex of young-adult carriers and noncarriers of APOEε4. At-risk ε4 carriers had lower mitochondrial cytochrome oxidase activity than noncarriers in posterior cingulate cortex, particularly within the superficial cortical lamina, a pattern similar to that seen in AD patients. Except for one 34 year-old ε4 homozygote, the ε4 carriers did not have increased soluble amyloid-β, histologic amyloid-β, or tau pathology in this same region. This functional biomarker may prove useful in early detection and tracking of AD and indicates that mitochondrial mechanisms may contribute to the predisposition to AD before any evidence of amyloid or tau pathology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-2010-100129

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mitochondrial dysfunction is involved in early AD pathology.

    “APOE4 carriers show mitochondrial dysfunction in brain areas associated with AD even before the onset of amyloid or tau pathology or cognitive changes, indicating that mitochondrial dysfunction is involved in early AD pathology [31].”

    From APOE4 Increases Energy Metabolism in APOE-Isogenic iPSC-Derived Neurons (2024) · cites this paper as [31]

    The Abstract reports reduced mitochondrial cytochrome oxidase activity in young APOE ε4 carriers’ posterior cingulate cortex, generally without detectable amyloid or tau pathology. But it identifies one carrier who did have both, and says mitochondrial mechanisms *may contribute* to AD predisposition; it does not establish that dysfunction is involved in early AD pathology. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • APOE4 carriers show mitochondrial dysfunction in brain areas associated with AD even before the onset of amyloid or tau pathology or cognitive changes.

    “APOE4 carriers show mitochondrial dysfunction in brain areas associated with AD even before the onset of amyloid or tau pathology or cognitive changes, indicating that mitochondrial dysfunction is involved in early AD pathology [31].”

    From APOE4 Increases Energy Metabolism in APOE-Isogenic iPSC-Derived Neurons (2024) · cites this paper as [31]

    The Abstract and Introduction report reduced mitochondrial cytochrome oxidase activity in young-adult APOE ε4 carriers in the posterior cingulate cortex, an AD-vulnerable region. The claim is broader than the evidence: the study measured mitochondrial activity in that region only, and the Results report one carrier who already had amyloid and tau pathology. The Abstract places the finding decades before possible symptom onset but does not establish the absence of cognitive changes in each donor. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • In nondemented apoE4 carriers, mitochondrial complex IV activity is decreased in cortical regions susceptible to Alzheimer's disease.

    “in nondemented apoE4 carriers, the activity of mitochondrial complex IV is decreased in cortical regions susceptible to AD [32]”

    From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [32]

    The Results report significantly lower cytochrome oxidase (mitochondrial complex IV) activity in young-adult APOE ε4 carriers than in noncarriers, but the measurements were from the posterior cingulate cortex. The Discussion says further studies are needed to determine whether the reduction extends beyond that region, so the claim's plural “cortical regions” is broader than this study establishes. Page numbers are unavailable in our copy. (LLM, conf=0.89)

    Experimental — accuracy not yet measured
  • Decrease in mitochondrial respiratory complex IV activity was observed in autopsy brains from young ApoE4 carriers.

    “a decrease in mitochondrial respiratory complex IV activity was observed in autopsy brains from young ApoE4 carriers [74]”
  • For many subjects with suspected AD or increased risk, what are currently considered downstream biomarker changes potentially precede upstream biomarker changes.

    “Our hypothesis, therefore, can accommodate a growing realization that for many subjects with suspected AD, or who have an increased risk of developing AD, what are currently considered downstream biomarker changes potentially precede upstream biomarker changes [206-213].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Valla, J., Yaari, R., Wolf, A. B., Kusne, Y., Beach, T. G., Roher, A. E., Corneveaux, J. J., Huentelman, M. J., Caselli, R. J., & Reiman, E. M.
Affiliations
  • Barrow Neurological Institute (US)
  • University of Arizona (US)
  • Banner Sun Health Research Institute (US)
  • Translational Genomics Research Institute (US)
  • Mayo Clinic in Arizona (US)
Corresponding author
Valla, Jon
Venue
Journal of Alzheimer s Disease
Published
2010-09-28
Volume
22
Issue
1
Pages
307-313
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W1529577194
Cited by
150
References
34
Citations by year
2026: 2 · 2025: 6 · 2024: 4 · 2023: 7 · 2022: 4 · 2021: 10 · 2020: 9 · 2019: 11 · 2018: 6 · 2017: 14 · 2016: 12 · 2015: 6 · 2014: 13 · 2013: 15 · 2012: 17
FWCI
9.97
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Aging (P30-AG-19610, R01-AG 19795, R01AG019795, R01AG031581, P30AG019610)
  • National Institute of Neurological Disorders and Stroke (R01NS059873)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords
APOE ε4, Alzheimer's disease
MeSH terms
Adolescent, Adult, Alleles, Alzheimer Disease, Electron Transport Complex IV, Female, Gyrus Cinguli, Genetic Carrier Screening, Humans, Male, Mitochondria, Genetic Predisposition to Disease, Apolipoprotein E4, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review